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Abstract
Background In contrast to surveys in cardiologist set-
tings, presentation and management of atrial ﬁbrillation
(AF) in primary care patients is less well studied.
Methods and results The prospective ATRIUM
(Outpatient Registry Upon Morbidity of Atrial Fibrillation)
collected data from patients with AF seen by 730 physi-
cians representing a random sample of all primary care
physicians in Germany. ATRIUM enrolled 3,667 patients
(mean age, 72 ± 9 years; 58% male, mean CHADS2 score
2.2 ± 1.3), 994 (27.1%) with paroxysmal, 944 (25.7%)
with persistent or long-standing persistent and 1,525
(41.6%) with permanent AF (no AF type was speciﬁed in
204 patients). Mean duration since initial diagnosis of AF
was 61 ± 66 months (median 42, interquartile range
14–88). Reported symptoms included palpitations (43%),
shortness of breath (49%), fatigue (49%), dizziness (37%)
and angina (20%). Most common concomitant conditions
were hypertension (84%), heart failure (43%), coronary
artery disease (345%), diabetes (35%) and chronic kidney
disease (20%). Prior myocardial infarction was present in
11% of patients, prior stroke in 10% and prior transient
ischemic attack in 10%. Antithrombotic medication was
used by 93% of the patients (oral anticoagulants, 83%).
Rate control therapy was reported in 75% and rhythm
control therapy in 33%, often added to rate control. Drugs
for rhythm and rate control included ß-blockers (75%),
calcium antagonists (15%), digitalis (29%), sodium chan-
nel blockers of type IA (quinidine, 1.0%) or IC (ﬂecainide
or propafenone, 5%), and potassium channel blockers
including amiodarone (11%). In the year prior to enroll-
ment, 46% of the patients had been cardioverted (23% by
drugs, 22% electrically), catheter ablation had been per-
formed in 5%, and 10% received a pacemaker or deﬁbril-
lator. A high proportion (44%) of the patients were
hospitalized in the year prior to enrollment.
Conclusions Patients with AF managed in primary care
often receive guideline-conforming therapy including
antithrombotic therapy, rate control and rhythm control
(numbers given above). Despite this apparent adherence,
almost half of the patients were hospitalized in the year
prior to enrollment, suggesting that the therapies applied do
not stabilize patients sufﬁciently to keep them out of
hospital.
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Atrial ﬁbrillation (AF) is the most commonly sustained
arrhythmia and affects at least 1% of the population in
Germany [1]. AF prevalence increases markedly with age,
resulting in an estimated two- to threefold increase in AF
patients in the next two decades [6, 31]. Many AF patients
suffer from concomitant conditions including hypertension,
vascular disease, heart failure and diabetes mellitus among
others. In addition to variable but often relevant symptoms,
AF appears to cause every fourth to ﬁfth stroke and is
associated with a doubling of mortality [34, 36].
AF management therefore consists of antithrombotic
therapy,whichisguidedbyclinicalstrokeriskestimation[1,
21], rate control therapy to improve left ventricular function
and symptoms during AF, and rhythm control therapy to
preventAFrecurrences.Despitethewidelyperceivednotion
that AF may cause severe complications, rhythm control
therapy using common drugs does not prevent deaths in AF
patients [11, 26, 33, 39], resulting in recommendations that
rhythm control therapy should be pursued in patients who
remain symptomatic on rate control [1].
Based on the variable presentation of AF and on slightly
differing recommendations in clinical practice, differences
in AF management depending on the type of treating
physician can be expected [24]. Unfortunately, most reg-
istry data so far report that most AF patients are managed
by cardiologists or other specialists.
We therefore initiated the prospective German ATRIUM
registry to characterize AF management in patients treated
by primary care physicians. Here, we report the baseline
observations of this registry.
Methods
Design ATRIUM (Outpatient Registry Upon Morbidity of
Atrial Fibrillation) is a prospective, multicenter, epidemi-
ological, non-interventional cohort study. ATRIUM
enrolled 3,667 patients in 730 primary care practices in
Germany in 2009. Baseline data included current man-
agement and information on interventions and complica-
tions in the year prior to enrollment. This data set is
reported here. The ethics committee of the Technical
University Dresden approved the study protocol. All
patients gave written consent prior to enrollment.
To draw a random sample of centers, a multi-step pro-
cedure was used in which more than 25,000 physicians
were contacted (Department of Medical Informatics,
Biometry and Epidemiology, University of Bochum).
Based on a comprehensive nationwide database of physi-
cians (Schwarzeck-Verlag), a representative sample of
25,000 primary care physicians was drawn by Abteilung
fu ¨r Medizinische Informatik, Biometrie und Epidemiolo-
gie, Ruhr-Universita ¨t Bochum. These physicians were
contacted via letter and informed about the study, and the
ﬁrst 730 respondents were offered participation. The cen-
ters agreed to consecutively enroll patients with AF doc-
umented by ECG in the 12 months prior to enrollment. No
exclusion criteria were deﬁned to minimize selection bias.
All data were recorded during an outpatient visit and
included information from the patient charts.
Parameters The following baseline parameters were
documented: age, sex, body weight, height, blood pressure,
risk factors for cardiovascular disease, cardiac history and
concomitant diseases. The CHADS2 score was speciﬁcally
recorded and the CHA2D2SVASc score, which was
recently proposed as a reﬁnement of the CHADS2 score
[1], was computed using the available information. In
addition, we recorded the month of initial diagnosis of AF,
type of AF (paroxysmal, persistent including long-lasting
persistent, or permanent), type of diagnostic tests per-
formed, suspected triggering factors of AF, therapy in the
year prior to enrollment, hospitalizations in the year prior
to enrollment and referral to a specialist. Drugs were
recorded by drug class. Quality of life was assessed by
EQ-5D in its validated German version [9].
Data analysis and statistics
All data were recorded on paper case report forms (CRF),
and double-entered by a contract research organization
(CRO Dr. Schauerte, Gru ¨nwald) into the study database.
A prespeciﬁed validation plan was used to check for
plausibility. Analysis was done by SAS Institute Inc.,
version 9.2 (Cary, NC, USA). Continuous parameters are
given as means ± standard deviation and categorical
parameters as the number of patients and percentages.
Continuous parameters were compared between groups
using ANOVA, and non-continuous parameters were
compared using chi-square test. Throughout the paper, two-
sided p values are given.
Results
Enrolling centers Of the 730 enrolling physicians (65%
males), 63% were primary care phsyicians (‘‘Facharzt fu ¨r
Allgemeinmedizin’’), 34% internists with a license and
practice in primary care (‘‘Internist in hausa ¨rztlicher
Praxis’’) and 4% practising physicians. Practices were
distributed among cities (29%), small towns (30%) and in
rural areas (40%, data not recorded in 0.7%) Enrolling
physicians were 50 ± 8 years old and worked in their
practice for an average of 14 ± 9 years or in a polyclinic
(‘‘Medizinisches Versorgungszentrum’’) for 9 ± 11 years.
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123Patient characteristics ATRIUM enrolled 3,667 patients,
58% male, with a mean age of 72 ± 9 years; 80% of the
patients were retired (Table 1). The mean age was higher in
patients with permanent AF than in those with paroxysmal
AF, most likely reﬂecting the progressive nature of AF and
the fact that older age was one of the factors that favored
rate control therapy [1]. Paroxysmal AF was present in 994
(26%) patients, persistent including long-standing persis-
tent AF in 944 (27%) and permanent AF in 1,525 (42%); in
204 patients (6%), AF type was not speciﬁed. Mean dura-
tion since the initial diagnosis of AF was 61 ± 66 months
(median 42, interquartile range, 14–88).
The mean CHADS2 score was 2.2 ± 1.3. The mean
CHA2DS2VASC score was 3.8 ± 1.7. CHA2DS2VASC
score was lower in patients with paroxysmal AF
(3.4 ± 1.7) compared to persistent AF (3.7 ± 1.6) or per-
manent AF (4.1 ± 1.7). Categorical distribution of scores
is shown in Fig. 1.
Reported symptoms included palpitations (43%), short-
ness of breath (49%), fatigue (49%), dizziness (37%) and
angina (20%). Most common concomitant conditions were
hypertension (84%), heart failure (43%), coronary artery
disease(35%),diabetes(35%)andchronicrenaldysfunction
(20%). Patients with a higher number of risk factors were
more frequent in the groups with permanent AF (Fig. 2).
Prior myocardial infarction was present in 11%, prior stroke
in 10% and prior transient ischemic attack in 10%.
Therapeutic goals Enrolling physicians reported the
following therapeutic goals: prevention of thromboembolic
events (77%), prevention of hospitalizations (57%),
reduction of cardiovascular mortality (61%), rate control
(76%) and rhythm control (33%; Table 2).
AF management Antithrombotic medication was used
by 93% of the patients (oral anticoagulants 83%, anti-
platelet drugs 27%, heparin 4%; Table 3). Contraindica-
tions for oral anticoagulants were reported in 6.4%. Of
the 3,667 patients, 262 had CHADS2 score 0 and 79
CHA2DS2-VASc score 0 and were therefore rated as not
eligible for OAC; 900 (CHADS2) and 240 (CHA2DS2-
VASc) patients had a score of 1 and were potentially eli-
gible; 2,486 (CHADS2) had a score C2 and thus were
eligible for OAC for anticoagulation according to the
guidelines in place at the time of the survey. [5, 28] Many
patients received OAC despite being not eligible according
to the scores (Fig. 3a, b). Further, of the 3,667 patients,
3,329 patients had a CHA2DS2-VASc score of 2 or more,
rendering approximately 90% of the surveyed patients
eligible for oral anticoagulation according to current rec-
ommendations [1]. Most patients at risk for stroke were
adequately anticoagulated (Fig. 2) and, especially in
patients without an indication for anticoagulation accord-
ing to CHADS2 score, over-anticoagulation was also found
(Fig. 2).
A total of 2,738 patients (75%) received rate control
therapy, while 16% received rhythm control therapy either
alone (189 patients; 5%) or in combination (404 patients;
11%). Drugs for rhythm and rate control included beta-
blockers (75%), calcium antagonists (15%), digitalis
(29%), potassium channel blockers including amiodarone
(11%), and sodium channel blockers of the type IA (usually
quinidine, 1.0%) or IC (usually ﬂecainide or propafenone,
5%). In the year prior to enrollment, 46% of the patients
had been cardioverted (23% by drugs and 22% electrically;
Table 4). Catheter ablation had been performed in 5%, and
10% received a pacemaker or deﬁbrillator.
A total of 1,602 patients (44%) were hospitalized in the
year prior to enrollment, with 772 patients having been
hospitalized more than once (Table 5). The mean hospi-
talization rates were somewhat higher for paroxysmal and
persistent AF compared to permanent AF (1.2 vs. 1.1 vs.
0.7 stays during 1 year).
In the surveyed period, only 41% of the patients fulﬁlled
the criteria for stable disease, deﬁned as stable medication
without AF-associated interventions.
Quality of life The EQ-5D was obtained from 3,460
patients. The mean EQ-5D index was 0.86 ± 0.19, close to
the maximum value of 1. The corresponding VAS, in
contrast, showed a mean value of 67 ± 18, indicating
reduced quality of life.
Discussion
The data from ATRIUM described here provide informa-
tion on the type of AF management in a sample of patients
in primary care collected through a random sample of
primary care physicians. Thereby, the report ﬁlls an
information gap, as most prior registries include predomi-
nantly patients managed by cardiologists and/or in hospi-
tals [2, 4, 17, 24, 27], which likely induced a selection bias
based on center selection. Another registry, similar to
ATRIUM, enrolled patients managed by German cardiol-
ogists [14]. Other information is available from population-
wide samples [3, 6–8, 12, 13, 16, 30, 34, 35, 37], but
information on the large proportion of patients managed as
outpatients in primary care is scarce [19, 20, 22]. The
central registry of the Germany AFNET more closely
reﬂects the situation of AF patients managed by different
types of physicians through enrollment of almost 10,000
patients from different levels of care [15, 23]. But even in
the AFNET registry, only 811 patients were enrolled by
primary care physicians (9%), demonstrating the need for
further data from this sector of health care [23].
Classiﬁcation ATRIUM enrolled a large unselected
cohort of outpatients with AF in different stages of their
disease (paroxysmal, persistent and permanent). We did
Clin Res Cardiol (2011) 100:897–905 899
123Table 1 Patient characteristics
Paroxysmal Persistent Permanent Tests
#
n = 994 n = 944 n = 1,525
n Value n Value n Value p
Demographics
Age (years) 69.8 ± 9.9 71.4 ± 9.1 73.7 ± 8.4 \0.0001
[65 years 725 72.9 729 77.2 1,307 85.7 \0.0001
Male 565 56.8 564 59.7 891 58.4 0.4435
Body mass index (kg/m
2) 28.4 ± 4.6 28.8 ± 4.8 28.6 ± 4.8 0.0851
§
Overweight 468 47.1 440 46.6 702 46.0 0.2291
Obese 300 30.2 324 34.3 488 32.0
Occupational status
Occupied 150 15.1 102 10.8 89 5.8 \0.0001
Retired 731 73.5 733 77.6 1,293 84.8
Prematurely retired 55 5.5 53 5.6 68 4.5
Other 54 5.4 55 5.7 72 4.8
Risk factors
Arterial hypertension 818 82.3 799 84.6 1,277 83.7 0.3875
Hyperlipidemia 611 61.5 574 60.8 912 59.8 0.7932
Diabetes mellitus 297 29.9 314 33.3 599 39.3 \0.0001
Smoking status 0.3971
Never 571 57.4 509 53.9 821 53.8
Previously 368 37.0 376 39.8 614 40.3
Currently 50 5.0 55 5.8 87 5.7
Hyperthyreosis 55 5.5 55 5.8 91 6.0 0.9508
Alcohol abuse 32 3.2 48 5.1 60 3.9 0.1271
Concomitant diseases
Chronic kidney disease 167 16.8 179 19.0 335 22.0 0.0051
Dialysis 1 0.6 1 0.6 4 1.2 0.6903
Serum creatinine (mg/dl) 1.4 ± 0.5 1.3 ± 0.5 1.4 ± 0.6 0.1850
Creatinine clearance (ml/min) 53.9 ± 20.9 56.6 ± 21.4 56.5 ± 18.1 0.7005
Transitory ischemic attack 105 10.6 83 8.8 158 10.4 0.3434
Prior stroke 101 10.2 82 8.7 160 10.5 0.3254
Ischemic 81 80.2 62 75.6 127 79.4 0.8450
Hemorrhagic 7 6.9 4 4.9 7 4.4
Cardiac risk factors/conditions
Coronary artery disease 302 30.4 315 33.4 587 38.5 \0.0001
Myocardial infarction 98 9.9 102 10.8 186 12.2 0.1345
PTCA 161 16.2 160 16.9 244 16.0 0.9075
Chronic heart failure 297 29.9 399 42.3 790 51.8 \0.0001
Highest NYHA stage in history
I 36 12.1 55 13.8 104 13.2 0.5018
II 107 36.0 153 38.3 323 40.9
III 95 32.0 130 32.6 243 30.8
IV 36 12.1 37 9.3 66 8.4
Current NYHA stage
I 111 37.4 147 36.8 292 37.0 0.8135
II 142 47.8 207 51.9 386 48.9
III 39 13.1 43 10.8 104 13.2
IV 1 0.3 1 0.3 5 0.6
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123not differentiate between ﬁrst diagnosed AF and other
forms of AF in this setting, as the classiﬁcation ‘‘ﬁrst
diagnosed AF’’ is more relevant in acute settings such as
emergency rooms or hospitals, as reﬂected by the rates of
ﬁrst diagnosed AF in the ALFA (26%) [19], Euro Heart
Survey (18%) [24] and AFNET [23] (11%) registries.
Patient characteristics in relation to other registries
Consistent with the expected ﬂow of management in which
patients with AF may be initially seen by a specialist, but
later continue their treatment in primary care [1], mean age
in ATRIUM (72 years) was higher than in the Euro Heart
Survey (69 ± 10 years) or the AFNET registry
(67 ± 13 years), and mean AF duration was over 5 years
(66 months). Males slightly outnumbered females, com-
parable to other surveys. As expected, concomitant con-
ditions were common, but there were slight differences:
arterial hypertension was more often found in ATRIUM
than in Euro Heart Survey (64%) or AFNET registries
(69%). Also, coronary artery disease was surprisingly
prevalent when compared with the aforementioned surveys
[23, 24]. Similar to the AFNET registry, permanent AF was
associated with more concomitant conditions.
Therapy and interventions In ATRIUM, 46% of the
patients underwent cardioversion in the year prior to
enrollment. Half of all cardioversions (23% of the total
patient cohort) were achieved by drugs, which represents a
higher rate than in MOVE (18%) [14], the AFNET registry
(3–16% depending on the AF type) [23] or the Euro Heart
Survey (3–14% depending on AF type) [24]. Electrical
cardioversion was also relatively frequent in ATRIUM
(22% in the total AF cohort) compared to AFNET (7–23%
depending on AF type), MOVE (18%), or the Euro Heart
Survey (3–24%) [14, 23][ 24].
The type of rate control therapy was not markedly
different from other trials and registries, with the exception
of slightly lower use of digitalis glycosides, potentially
already reﬂecting the growing experience that these agents
only control heart rate well in sedentary patients [14, 23].
In ATRIUM, almost all patients received (any) anti-
thrombotic therapy (92.5%), suggesting that stroke pre-
vention was a ﬁrmly established therapeutic goal in the
Fig. 1 CHA2DS2-VASc score. Score points based on available data
for the calculation of the score in 3,667 patients
Fig. 2 Numbers of concomitant conditions, by AF type. Risk factors:
age C75 years, arterial hypertension, diabetes mellitus and chronic
heart failure. Values are missing for AF type in 204 patients and for
concomitant conditions in 18 patients
Table 1 continued
Paroxysmal Persistent Permanent Tests
#
n = 994 n = 944 n = 1,525
n Value n Value n Value p
AF
Atrial ﬁbrillation 911 91.6 884 93.6 1,488 97.6 \0.0001
Atrial ﬂutter 72 7.2 63 6.7 24 1.6 \0.0001
CHADS2 score 1.9 ± 1.2 2.1 ± 1.2 2.4 ± 1.3 \0.0001
CHA2DS2-VASc 3.4 ± 1.7 3.7 ± 1.6 4.1 ± 1.7 \0.0001
# v
2-test or F test for analysis of variance (ANOVA)
§ Nonparametric Kruskal–Wallis test, p = 0.0415
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123primary care setting. Furthermore, over 70% of patients
with an evidence-based indication for oral anticoagulation
received such therapy, a high proportion compared to other
surveys. [38] Consistent with other registries [23, 25], a
substantial portion of patients potentially ineligible for oral
anticoagulation received such therapy (Fig. 3). This may in
part reﬂect the ‘‘subconscious’’ application of a broader
indication of anticoagulation in AF patients, as formalized
in the CHA2DS2VASc score [1, 21]. Furthermore, the
parameter ‘‘vascular disease’’ was somewhat underreported
in this survey, as the components atherosclerosis of the
aorta and peripheral arterial disease, were not recorded in
the CRF.
Frequent hospitalizations despite enrollment of
presumably ‘‘stable’’ patients The outpatient setting of
ATRIUM also resulted in a high proportion of patients with
permanent AF (42%, more than in Euro Heart Survey (29%)
or AFNET (33%)), consistent with the AFNET data set
showing a higher proportion of patients with permanent AF
in outpatient centers [23]. The mean hospitalization rates
were higher in paroxysmal and persistent AF compared to
permanent AF, which is in contrast to earlier ﬁndings in the
COCAF study [18]. Despite relatively frequent hospital-
izations, the mean quality of life score in ATRIUM was
slightly better than in the Euro Heart Survey (EQ-5D men
0.85, women 0.73) [24]. The outpatient setting and the
Table 2 Goals of therapy
Paroxysmal Persistent Permanent Tests
#
n = 994 n = 944 n = 1,525
n % n % n % p
Prevention of thrombo-embolic complications 718 72.2 728 77.1 1,238 81.2 \0.0001
Prevention of hospitalizations 537 54.0 524 55.5 943 61.8 \0.0001
Reduction of cardiovascular mortality 553 55.6 568 60.2 1,020 66.9 \0.0001
Rhythm control 623 62.7 336 35.6 205 13.4 \0.0001
Rate control 596 60.0 722 76.5 1,301 85.3 \0.0001
Other 52 5.2 65 6.9 81 5.3 0.1961
Percentages did not sum up to 100% because multiple answers were possible
# v
2-test
Table 3 Therapy in the previous 12 months
Paroxysmal Persistent Permanent Tests
#
n = 994 n = 944 n = 1,525
n Value n Value n Value p
Antiarrhythmic drugs class
IA 13 1.3 13 1.4 7 0.5 0.0273
Duration (months) 9.4 ± 4.4 10.2 ± 3.1 9.3 ± 4.4 0.8008
IC 107 10.8 46 4.9 27 1.8 \0.0001
Duration (months) 9.0 ± 4.1 7.0 ± 4.7 9.5 ± 4.3 \0.0001
II 754 75.9 724 76.7 1,112 72.9 0.0122
Duration (months) 10.1 ± 3.4 9.8 ± 3.7 11.5 ± 1.9 \0.0001
III 140 14.1 119 12.6 112 7.3 \0.0001
With ß-blocker activity 54 5.4 52 5.5 76 5.0 0.7330
Duration (months) 8.9 ± 4.4 9.3 ± 3.7 10.5 ± 3.3 0.0593
Other 83 8.4 65 6.9 35 2.3 \0.0001
Duration (months) 7.8 ± 4.4 6.7 ± 4.4 9.6 ± 3.3 0.0052
IV 130 13.1 140 14.8 273 17.9 0.0046
Duration (months) 9.8 ± 3.9 9.8 ± 3.6 11.5 ± 1.9 \0.0001
Digitalis 204 20.5 262 27.8 547 35.9 \0.0001
Duration (months) 9.4 ± 4.0 8.8 ± 4.1 11.3 ± 2.3 \0.0001
# v
2-test or F test for analysis of variance (ANOVA)
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123permanent nature of AF render the number of patients with
hospitalizations and ‘‘unstable disease’’ in our cohort
remarkable, especially when this number was compared to
the markedly lower hospitalization rate (about 25–27%) in
large, recently published trials in AF patients such as
ADONIS/EURIDIS [29], ATHENA [10] and RACE II [32].
While it is conceivable that lower hospitalization rates in
trials reﬂect a selection bias toward ‘‘healthier’’ patients and
possibly better overall management owing to the close
follow-up regimen in clinical trials, the reasons for hospi-
talizations in this ‘‘all-comer’’ population with long-stand-
ing AF are worthy of further study.
Fig. 3 Antithrombotic prophylaxis and oral anticoagulation (OAC)
in patients with various eligibility categories for OAC by CHADS2 or
CHA2DS2-VASc. Score 0 (=no risk factor) = no OAC recom-
mended; Score 1 (=only 1 non-major risk factor) = either ASS or
OAC recommended, OAC preferred; Score C2 (=at least 1 major or at
least 2 non-major risk factors) = OAC recommended. Information on
antithrombotic prophylaxis and oral anticoagulation was missing in
409 patients
Table 4 Pharmacological and electrical conversions
n %
Pharmacological (drug) conversion 855 23.3
Ambulatory 351 41.1
Hospital based 454 53.1
Ambulatory/hospital based 26 3.0
Unknown 24 2.8












Duration since last conversion (months); n = 794
a
Mean ± SD 27.4 ± 40.5
Median 11.0
Range 0.0–340.0
Electrical conversion 820 22.4
Ambulatory 62 7.6
Hospital based 684 83.4
Ambulatory/hospital based 4 0.5
Unknown 70 8.5








Duration since last conversion (months); n = 751
a
Mean ± SD 30.3 ± 37.8
Median 14.0
Range 0.0–286.0
Catheter ablation 194 5.3
Implantation of pacemaker/deﬁbrillators 384 10.5
Data from 3,367 patients
SD standard deviation
a Subpopulation with information on duration since last conversion
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123Methodological considerations In selecting centers, care
was taken to represent all regions in Germany equally.
Nonetheless, it is conceivable that there remained a
selection bias for centers with interest and/or expertise in
AF management associated with the agreement to partici-
pate. Further limitations of this study are possible reporting
bias (e.g., underreporting of diseases by physicians), mis-
classiﬁcation of disease (e.g., AF type), selection bias of
patients (only those willing to participate), neglect of
patient-related factors such as treatment compliance and
patient recall bias (e.g., on number of procedures or hos-
pitalizations in the previous 12 months). Despite the sys-
tematic process for selecting participating centers (see
‘‘Methods’’), selection bias of participating physicians is
also possible. Furthermore, it was not possible to verify
consecutive enrollment or the completeness of the infor-
mation on the paper CRF by source data monitoring.
Conclusion
ATRIUM provides a hitherto unknown insight into details
of current AF management in primary care in Germany.
The good overall antithrombotic management is remark-
able, but the frequent AF-related hospitalizations and the
overall, often unstable, course of AF indicate unsolved
problems. Challenges in the treatment of AF in these often
multimorbid patients (with high rates of coronary artery
disease and hypertension, for example) pose challenges to
treating physicians.
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